China's NMPA approves 15 home-grown drugs in biotech boom
Record $60B licensing deals and 73% surge in out-licensing signal global shift.
Get AI news that actually matters
One email a day. Zero fluff. Join 10,000+ professionals.
China's drug regulator, the National Medical Products Administration (NMPA), has approved 19 innovative drugs for sale so far in 2026, with 15 of them originating from domestic biotech companies. This includes sonrotoclax, developed by BeOne, for treating certain adult blood cancers. The approvals underscore a broader biotech boom in China, driven by an overhauled approval process that fast-tracks home-grown therapies.
Investment in R&D is accelerating: Fosun Pharma allocated 4.3 billion yuan (US$634 million) to innovative drug development last year, a 16% increase from 2024 and over 80% of its total research budget. Meanwhile, Chinese biotech firms struck a record US$60 billion in cross-border licensing deals in Q1 2026 alone—a 73% year-on-year surge and nearly half the total for all of 2025 (US$135.7 billion). Multinational corporations are aggressively acquiring early-stage drugs from China's pipeline, reflecting the country's rising role as a global innovation hub in biotech.
- NMPA approved 19 innovative drugs in 2026; 15 from domestic firms including BeOne's sonrotoclax.
- Fosun Pharma's R&D spending hit 4.3B yuan ($634M), up 16% year-over-year.
- Cross-border licensing deals reached $60B in Q1 2026, a 73% surge from Q1 2025.
Why It Matters
China's biotech surge and faster approvals reshape global pharma R&D and licensing dynamics.